Although tumor PD-L1 expression has been associated with anti-PD1/PD-L1 ICI response in multiple cancers (including non-small cell lung, bladder, cervical, and triple-negative breast cancer), this immunohistochemical marker has not yet proven to be a good predictor of response for HCC[3,4]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.